Natural-product-derived fragments for fragment-based ligand discovery

Nature Chemistry

Volumn 5, Issue 1, 2013, Pages 21-28

  Over, Björn ^a,b   Wetzel, Stefan ^a   Grütter, Christian ^b,c   Nakai, Yasushi ^a,e   Renner, Steffen ^a,d   Rauh, Daniel ^b,c   Waldmann, Herbert ^a,b  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

^c CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 14; QUINONE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ALGORITHM; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; IC 50; MOLECULAR LIBRARY; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; INHIBITORY CONCENTRATION 50; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR STRUCTURE; QUINONES; SMALL MOLECULE LIBRARIES; TETRAHYDROISOQUINOLINES;

EID: 84871599677     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.1506     Document Type: Article

References (46)

1. Murray, C. W. & Rees, D. C. The rise of fragment-based drug discovery. Nature Chem. 1, 187-192 (2009).
2. Roughley, S. D. & Hubbard, R. E. How well can fragments explore accessed chemical space? A case study from heat shock protein 90. J. Med. Chem. 54, 3989-4005 (2011).
3. Chessari, G. & Woodhead, A. J. From fragment to clinical candidate - a historical perspective. Drug Discov. Today 14, 668-675 (2009).
4. Babaoglu, K. & Shoichet, B. K. Deconstructing fragment-based inhibitor discovery. Nature Chem. Biol. 2, 720-723 (2006).
5. Hubbard, R. E., Chen, I. & Davis, B. Informatics and modeling challenges in fragment-based drug discovery. Curr. Opin. Drug Discov. Dev. 10, 289-297 (2007).
6. Siegel, M. G. & Vieth, M. Drugs in other drugs: a new look at drugs as fragments. Drug Discov. Today 12, 71-79 (2007).
7. Nicholls, A. et al. Molecular shape and medicinal chemistry: a perspective. J. Med. Chem. 53, 3862-3886 (2010).
8. Ritchie, T. J., Macdonald, S. J. F., Young, R. J. & Pickett, S. D. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov. Today 16, 164-171 (2011).
9. Lovering, F., Bikker, J. & Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752-6756 (2009).
10. Hung, A. W. et al. Route to three-dimensional fragments using diversityoriented synthesis. Proc. Natl Acad. Sci. USA 108, 6799-6804 (2011).
11. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311-335 (2012).
12. Wetzel, S., Schuffenhauer, A., Roggo, S., Ertl, P. & Waldmann, H. Cheminformatic analysis of natural products and their chemical space. Chimia Int. J. Chem. 61, 355-360 (2007).
13. Grabowski, K., Baringhaus, K-H. & Schneider, G. Scaffold diversity of natural products: inspiration for combinatorial library design. Nat. Prod. Rep. 25, 892-904 (2008).
14. Congreve, M., Carr, R., Murray, C. & Jhoti, H. A 'Rule of Three' for fragmentbased lead discovery? Drug Discov. Today 8, 876-877 (2003).
15. Köster, H. et al. A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. J. Med. Chem. 54, 7784-7796 (2011).
16. Wetzel, S., Bon, R. S., Kumar, K. & Waldmann, H. Biology-oriented synthesis. Angew. Chem. Int. Ed. 50, 10800-10826 (2011).
17. Bon, R. S. & Waldmann, H. Bioactivity-guided navigation of chemical space. Acc. Chem. Res. 43, 1103-1114 (2010).
18. Kumar, K. & Waldmann, H. Synthesis of natural product inspired compound collections. Angew. Chem. Int. Ed. 48, 3224-3242 (2009).
19. Schuffenhauer, A. et al. The scaffold tree; visualization of the scaffold universe by hierarchical scaffold classification. J. Chem. Inf. Model. 47, 47-58 (2007).
20. Koch, M. A. et al. Charting biologically relevant chemical space: a structural classification of natural products (SCONP). Proc. Natl Acad. Sci. USA 102, 17272-17277 (2005).
21. Dictionary of Natural Products Version 18.2, 2009 (Chapman & Hall/CRC Press, 2009).
22. Bemis, G. W. & Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39, 2887-2893 (1996).
23. Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S. & Coleman, R. G. ZINC: a free tool to discover chemistry for biology. J. Chem. Inf. Model. 52, 1757-1768 (2012).
24. Butina, D. Unsupervised data base clustering based on daylight's fingerprint and Tanimoto similarity: a fast and automated way to cluster small and large data sets. J. Chem. Inf. Comput. Sci. 39, 747-750 (1999).
25. Gill, A. L. et al. Identification of novel p38a MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 48, 414-426 (2004).
26. Pollack, S. et al. A comparative study of fragment screening methods on the p38a kinase: new methods, new insights. J. Comput. Aided Molec. Des. 25, 677-687 (2011).
27. Goettert, M., Schattel, V., Koch, P., Merfort, I. & Laufer, S. Biological evaluation and structural determinants of p38a mitogen-activated- protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids. ChemBioChem 11, 2579-2588 (2010).
28. +)-sparteine-like diamines for asymmetric synthesis. J. Org. Chem. 69, 5789-5792 (2004).
29. Simard, J. R. et al. A new screening assay for allosteric inhibitors of cSrc. Nature Chem. Biol. 5, 394-396 (2009).
30. Rabiller, M. et al. Proteus in the world of proteins: conformational changes in protein kinases. Arch. Pharm. (Weinheim) 343, 193-206 (2010).
31. Ahn, Y. M. et al. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorg. Med. Chem. Lett. 20, 5793-5798 (2010).
32. Swann, S. L. et al. Biochemical and biophysical characterization of unique switch pocket inhibitors of p38a. Bioorg. Med. Chem. Lett. 20, 5787-5792 (2010).
33. Getlik, M. et al. Structure-based design, synthesis and biological evaluation of N-pyrazole, N′-thiazole urea inhibitors of MAP kinase p38a. Eur. J. Med. Chem. 48, 1-15 (2012).
34. Kaiser, M., Wetzel, S., Kumar, K. & Waldmann, H. Biology-inspired synthesis of compound libraries. Cell. Mol. Life Sci. 65, 1186-1201 (2008).
35. Vintonyak, V. V., Antonchick, A. P., Rauh, D. & Waldmann, H. The therapeutic potential of phosphatase inhibitors. Curr. Opin. Chem. Biol. 13, 272-283 (2009).
36. Vintonyak, V. V., Waldmann, H. & Rauh, D. Using small molecules to target protein phosphatases. Bioorg. Med. Chem. 19, 2145-2155 (2011).
37. Bialy, L. & Waldmann, H. Inhibitors of protein tyrosine phosphatases: next-generation drugs? Angew. Chem. Int. Ed. 44, 3814-3839 (2005).
38. Nören-Müller, A. et al. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc. Natl Acad. Sci. USA 103, 10606-10611 (2006).
39. Renner, S. et al. Bioactivity-guided mapping and navigation of chemical space. Nature Chem. Biol. 5, 585-592 (2009).
40. Hert, J., Irwin, J. J., Laggner, C., Keiser, M. J. & Shoichet, B. K. Quantifying biogenic bias in screening libraries. Nature Chem. Biol. 5, 479-483 (2009).
41. Hessler, G. & Baringhaus, K-H. The scaffold hopping potential of pharmacophores. Drug Discov. Today: Technologies 7, e263-e269 (2010).
42. Nisius, B. & Rester, U. Fragment shuffling: an automated workflow for three-dimensional fragment-based ligand design. J. Chem. Inf. Model. 49, 1211-1222 (2009).
43. Bamborough, P., Brown, M. J., Christopher, J. A., Chung, C-W. & Mellor, G. W. Selectivity of kinase inhibitor fragments. J. Med. Chem. 54, 5131-5143 (2011).
44. Varin, T., Schuffenhauer, A., Ertl, P. & Renner, S. Mining for bioactive scaffolds with scaffold networks: improved compound set enrichment from primary screening data. J. Chem. Inf. Model. 51, 1528-1538 (2011).
45. Wetzel, S. et al. Interactive exploration of chemical space with scaffold hunter. Nature Chem. Biol. 5, 581-583 (2009).
46. Steinbeck C. et al. Recent developments of the chemistry development kit (CDK) - an open-source Java library for chemo- and bioinformatics. Curr. Pharmaceut. Des. 1217, 2111-2120 (2006).